NMDA receptor expression during cell transformation process at early stages of liver cancer in rodent models
Hepatocellular carcinoma (HCC) is the most common primary liver cancer, which is not sensitive to radiotherapy and chemotherapy and very often experiences postoperative relapse. In this regard, effective screening of liver cancer is considered as the most important and urgent task. The aim of our study was to determine whether N-methyl-D-aspartate receptor (NMDAR) and, in particular, its subunits, can serve as biomarkers to distinguish the precancerous liver at early stages of liver fibrosis. We assessed the development of HCC after 10, 15, and 22 wk using a HCC rat model. The expression of NMDAR subunits was monitored at different stages of HCC by means of immunohistochemistry combined with epifluorescence microscopy imaging, Western blotting, and direct bisulfite sequencing. NMDAR subunits were not found in healthy liver tissues. In contrast, NMDAR subunits, in particular NR1 and NR2B, appeared at the stage of severe liver fibrosis (precancerous liver disease) in rats and were expressed during the development of HCC in rats and mice. Using the direct bisulfite sequencing, we detected that increased expression of NMDAR directly correlated with the demethylation of CpG islands in the promoter region of genes encoding receptor subunits. The obtained results confirmed that NMDAR subunits can serve as new biomarkers of precancerous liver disease, severe fibrosis, and its progression towards HCC.NEW & NOTEWORTHY We have shown NMDAR expression in cell transformation process at early stages of cancer, specifically HCC. The aim of our study was to define the disease stages from precancerous liver disease towards liver cancer progression when NMDAR subunits were expressed/detected. A fibrosis/HCC rat model, immunohistochemistry combined with epifluorescence microscopy imaging, Western blotting was used. The dynamics of appearance of NMDAR subunits, their expression and methylation status during the development of HCC were shown and discussed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:322 |
|---|---|
| Enthalten in: |
American journal of physiology. Gastrointestinal and liver physiology - 322(2022), 1 vom: 01. Jan., Seite G142-G153 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Stepanov, Yurii V [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 10.02.2022 Date Revised 10.02.2022 published: Print-Electronic figshare: 10.6084/m9.figshare.14014946 Citation Status MEDLINE |
|---|
| doi: |
10.1152/ajpgi.00060.2021 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM333886097 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM333886097 | ||
| 003 | DE-627 | ||
| 005 | 20231225222551.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1152/ajpgi.00060.2021 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1112.xml |
| 035 | |a (DE-627)NLM333886097 | ||
| 035 | |a (NLM)34851733 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Stepanov, Yurii V |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a NMDA receptor expression during cell transformation process at early stages of liver cancer in rodent models |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.02.2022 | ||
| 500 | |a Date Revised 10.02.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a figshare: 10.6084/m9.figshare.14014946 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Hepatocellular carcinoma (HCC) is the most common primary liver cancer, which is not sensitive to radiotherapy and chemotherapy and very often experiences postoperative relapse. In this regard, effective screening of liver cancer is considered as the most important and urgent task. The aim of our study was to determine whether N-methyl-D-aspartate receptor (NMDAR) and, in particular, its subunits, can serve as biomarkers to distinguish the precancerous liver at early stages of liver fibrosis. We assessed the development of HCC after 10, 15, and 22 wk using a HCC rat model. The expression of NMDAR subunits was monitored at different stages of HCC by means of immunohistochemistry combined with epifluorescence microscopy imaging, Western blotting, and direct bisulfite sequencing. NMDAR subunits were not found in healthy liver tissues. In contrast, NMDAR subunits, in particular NR1 and NR2B, appeared at the stage of severe liver fibrosis (precancerous liver disease) in rats and were expressed during the development of HCC in rats and mice. Using the direct bisulfite sequencing, we detected that increased expression of NMDAR directly correlated with the demethylation of CpG islands in the promoter region of genes encoding receptor subunits. The obtained results confirmed that NMDAR subunits can serve as new biomarkers of precancerous liver disease, severe fibrosis, and its progression towards HCC.NEW & NOTEWORTHY We have shown NMDAR expression in cell transformation process at early stages of cancer, specifically HCC. The aim of our study was to define the disease stages from precancerous liver disease towards liver cancer progression when NMDAR subunits were expressed/detected. A fibrosis/HCC rat model, immunohistochemistry combined with epifluorescence microscopy imaging, Western blotting was used. The dynamics of appearance of NMDAR subunits, their expression and methylation status during the development of HCC were shown and discussed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a N-methyl-d-aspartate receptor | |
| 650 | 4 | |a NMDAR subunit | |
| 650 | 4 | |a hepatocellular carcinoma | |
| 650 | 4 | |a liver fibrosis | |
| 650 | 4 | |a precancerous conditions | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 650 | 7 | |a Receptors, N-Methyl-D-Aspartate |2 NLM | |
| 700 | 1 | |a Golovynska, Iuliia |e verfasserin |4 aut | |
| 700 | 1 | |a Dziubenko, Nataliia V |e verfasserin |4 aut | |
| 700 | 1 | |a Kuznietsova, Halyna M |e verfasserin |4 aut | |
| 700 | 1 | |a Petriv, Nataliia |e verfasserin |4 aut | |
| 700 | 1 | |a Skrypkina, Inessa |e verfasserin |4 aut | |
| 700 | 1 | |a Golovynskyi, Sergii |e verfasserin |4 aut | |
| 700 | 1 | |a Stepanova, Liudmyla I |e verfasserin |4 aut | |
| 700 | 1 | |a Stohnii, Yevhenii |e verfasserin |4 aut | |
| 700 | 1 | |a Garmanchuk, Liudmyla V |e verfasserin |4 aut | |
| 700 | 1 | |a Ostapchenko, Liudmyla I |e verfasserin |4 aut | |
| 700 | 1 | |a Yevsa, Tetyana |e verfasserin |4 aut | |
| 700 | 1 | |a Qu, Junle |e verfasserin |4 aut | |
| 700 | 1 | |a Ohulchanskyy, Tymish Y |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of physiology. Gastrointestinal and liver physiology |d 2000 |g 322(2022), 1 vom: 01. Jan., Seite G142-G153 |w (DE-627)NLM105735175 |x 1522-1547 |7 nnns |
| 773 | 1 | 8 | |g volume:322 |g year:2022 |g number:1 |g day:01 |g month:01 |g pages:G142-G153 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1152/ajpgi.00060.2021 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 322 |j 2022 |e 1 |b 01 |c 01 |h G142-G153 | ||